Additional Proxy Soliciting Materials (definitive) (defa14a)
July 02 2021 - 07:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule
14a-101)
PROXY STATEMENT PURSUANT TO
SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
| Filed by the Registrant
x |
|
Check the appropriate box:
|
¨ |
Preliminary Proxy Statement |
|
¨ |
Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2)) |
|
¨ |
Definitive Proxy Statement |
|
x |
Definitive Additional Materials |
|
¨ |
Soliciting Material Pursuant to sec. 240.14a-11(c) or sec.
240.14a-12 |
NEUBASE
THERAPEUTICS, INC.
(Name of
Registrant as Specified in Its Charter)
N/A
(Name of
Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment of Filing Fee (Check the appropriate box):
|
¨ |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1)
and 0-11. |
|
(1) |
Title of each class of securities to which transaction
applies: |
| |
|
|
|
(2) |
Aggregate number of securities to which transaction
applies: |
| |
|
|
|
(3) |
Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (Set forth the amount
on which the filing fee is calculated and state how it was
determined): |
| |
|
|
|
(4) |
Proposed maximum aggregate value of transaction: |
| |
|
|
|
¨ |
Fee paid previously with
preliminary materials. |
|
¨ |
Check box if any part of the fee is offset as provided by
Exchange Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by
registration statement number, or the Form or Schedule and the date
of its filing. |
|
(1) |
Amount Previously Paid: |
| |
|
|
|
(2) |
Form, Schedule or Registration State No.: |
| |
|
|
|
|
NeuBase Therapeutics,
Inc. Important Notice Regarding the Availability of Proxy Materials
Stockholders Meeting to be held on August 18, 2021 For Stockholders
as of record on June 24, 2021 Have the 12 digit control number
located in the shaded box above available when you access the
website and follow the instructions. When requesting via the
Internet or telephone you will need the 12 digit control number
located in the shaded box above. * If requesting material by
e-mail, please send a blank e-mail with the 12 digit control number
(located above) in the subject line. No other requests,
instructions OR other inquiries should be included with your e-mail
requesting material. NeuBase Therapeutics, Inc. Meeting Type: Date:
Time: Place: Annual Meeting of Stockholders Wednesday, August 18,
2021 10:00 AM, Eastern Time Annual Meeting to be held live via the
Internet please visit www.proxydocs.com/NBSE for more details. You
must register to attend the meeting online and/or participate at
www.proxydocs.com/NBSE SEE REVERSE FOR FULL AGENDA INTERNET
www.investorelections.com/NBSE TELEPHONE (866) 648-8133 * E-MAIL
paper@investorelections.com To order paper materials, use one of
the following methods. For a convenient way to view proxy materials
and VOTE go to www.proxydocs.com/NBSE If you want to receive a
paper or e-mail copy of the proxy material, you must request one.
There is no charge to you for requesting a copy. In order to
receive a paper package in time for this year's meeting, you must
make this request on or before August 09, 2021. This communication
presents only an overview of the more complete proxy materials that
are available to you on the Internet. This is not a ballot. You
cannot use this notice to vote your shares. We encourage you to
access and review all of the important information contained in the
proxy materials before voting. To view the proxy materials, and to
obtain directions to attend meeting, go to: www.proxydocs.com/NBSE
To vote your proxy while visiting this site, you will need the 12
digit control number in the box below. Under United States
Securities and Exchange Commission rules, proxy materials do not
have to be delivered in paper. Proxy materials can be distributed
by making them available on the internet. P.O. BOX 8016, CARY, NC
27512-9903
|
|
|
NeuBase Therapeutics,
Inc. Annual Meeting of Stockholders PROPOSAL 1 To elect two Class I
Directors, Dov A. Goldstein, MD, and Eric I Richman, nominated by
our Board of Directors, to serve until our 2024 Annual Meeting of
Stockholders and until their successors are duly elected and
qualified. 1.01 Dov A. Goldstein, MD 1.02 Eric I. Richman 2. To
ratify the selection of Marcum LLP as our independent registered
public accounting firm for the fiscal year ending September 30,
2021 3 To approve, on an advisory basis, the compensation paid to
the Company's Named Executive Officers, as disclosed pursuant to
Item 402 of Regulation S-K, including the compensation tables and
narrative discussion within the section of the Company's Proxy
Statement entitled "Executive Compensation." 4 To transact such
other business as may properly come before the Annual Meeting or
any adjournment thereof. THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR ON PROPOSALS 1, 2 AND 3
|
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Apr 2022 to May 2022
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From May 2021 to May 2022
